Table 1

Baseline characteristics of study populations

Patients with
COVID-19
(n=52)
Comorbidity-matched
volunteers
(n=26)
Healthy
volunteers
(n=10)
P value*P value†
Age, median (IQR) (years)55 (51–57)53 (47–57)35 (29–40)0.58<0.0001
Male39 (75)19 (73)9 (90)
Body mass index, median (IQR) (kg/m2)28 (18–42)27 (22–41)21 (22–27)0.26<0.001
Time of scan post symptoms onset median±IQR (days)90±(7–290)
Persistent symptoms, n (%)20 (38)
Intensive care admission, n (%)15 (29)
Endotracheal intubation, n (%)5 (10)
Non-invasive ventilation, n (%)6 (12)
Quick COVID-19 severity index, n (%)
 Low21 (40)
 Low intermediate13 (25)
 High intermediate14 (27)
 High4 (8)
Medical history, n (%)
 Hypertension18 (35)8 (31)
 Ischaemic heart disease8 (15)5 (19)
 Hypercholestrolaemia16 (31)8 (31)
 Atrial fibrillation/flutter2 (4)1 (4)
 Previous cerebrovascular event1 (2)0
 Diabetes mellitus18 (35)11 (38)
 Non-cardiac17 (33)2 (8)
Medications, n (%)
 Antiplatelet therapy9 (17)6 (23)
 Beta-blocker therapy8 (15)4 (15)
 ACE inhibitor or angiotensin receptor blocker therapy14 (27)9 (35)
 Diuretic therapy2 (4)0
 Statin therapy16 (31)10 (38)
 Antiglycaemic therapy18 (35)11 (42)
Smoking status, n (%)
 Non-smoker43 (83)14 54)0
 Ex-smoker8 (15)10 (38)0
 Current smoker01 (4)0
  • *Patients with COVID-19 versus comorbidity-matched volunteers.

  • †Patients with COVID-19 versus healthy volunteers.